期刊
EUROPEAN JOURNAL OF CANCER
卷 113, 期 -, 页码 41-44出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2019.02.014
关键词
Immunotherapy; Tumor immunology; Chemotherapy; Combination; Survival
类别
资金
- Olivia Fund [2017/LUF/00135]
- Amgen Chair for Therapeutic Advances in Ovarian Cancer [2017/LUF/00069]
Because of the failure of immunotherapy as single agent in a number of cancers, current clinical trials are focusing on combining immunotherapy with other therapies. The most frequently chosen combination for immunotherapy is chemotherapy. However, almost no preclinical data on this combination is available. Some studies even showed a dismal effect of combining chemotherapy with immunotherapy. Taken into account that each of the therapies chosen in a combination will influence the cancer cells but also immune effector cells as well as immunosuppressive cells, and that these three partners will also interact with each other, launching a combination to the patient without proper immune monitoring and preclinical evidence might be devastating. (C) 2019 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据